NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
Updated: Feb 5
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
Sponsor
ClinicalTrials.gov Identifier: NCT05347485
Official Title: A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma
First Posted: April 26, 2022
Click here for details on ClinicalTrials.gov
CART
JNJ-68284528
Ciltacabtagene Autoleucel
Drug: Cilta-cel
Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
Locations
United States, California
United States, Colorado
United States, Florida
United States, Georgia
United States, Illinois
United States, Kansas
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, New York
United States, North Carolina
United States, Pennsylvania
United States, Texas
United States, Washington
United States, Wisconsin